PHA-848125
CAS No. 802539-81-7
PHA-848125 ( Milciclib;PHA 848125 )
Catalog No. M16004 CAS No. 802539-81-7
A potent, selective, brain penetrant and orally available dual CDK and TRK inhibitor with IC50 of 45 and 53 nM for CDK2/cyclin A and TrkA, respectively; shows cross-reactivity with other CDKs (CDK1/4/5/7), TrkB/C, Kit, Abl and PDGFR (IC50s<1 uM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 178 | In Stock |
|
10MG | 291 | In Stock |
|
25MG | 492 | In Stock |
|
50MG | 709 | In Stock |
|
100MG | 972 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePHA-848125
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, brain penetrant and orally available dual CDK and TRK inhibitor with IC50 of 45 and 53 nM for CDK2/cyclin A and TrkA, respectively; shows cross-reactivity with other CDKs (CDK1/4/5/7), TrkB/C, Kit, Abl and PDGFR (IC50s<1 uM).
-
DescriptionA potent, selective, brain penetrant and orally available dual CDK and TRK inhibitor with IC50 of 45 and 53 nM for CDK2/cyclin A and TrkA, respectively; shows cross-reactivity with other CDKs (CDK1/4/5/7), TrkB/C, Kit, Abl and PDGFR (IC50s<1 uM); nhibits cell proliferation of a wide panel of tumoral cell lines with submicromolar IC50; shows significant antitumor activity in various human xenografts.Brain Cancer Phase 2 Clinical
-
SynonymsMilciclib;PHA 848125
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK2/CyclinA; CDK4/CyclinD1; CDK5/p35; CDK7/CyclinH; TrkA
-
Research AreaCancer
-
IndicationBrain Cancer
Chemical Information
-
CAS Number802539-81-7
-
Formula Weight460.57
-
Molecular FormulaC25H32N8O
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(C1=NN(C)C2=C1C(C)(C)CC3=CN=C(NC4=CC=C(N5CCN(C)CC5)C=C4)N=C23)NC
-
Chemical Name1H-Pyrazolo[4,3-h]quinazoline-3-carboxamide, 4,5-dihydro-N,1,4,4-tetramethyl-8-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Brasca MG, et al. J Med Chem. 2009 Aug 27;52(16):5152-63.
2. Degrassi A, et al. Mol Cancer Ther. 2010 Mar;9(3):673-81.
3. Albanese C, et al. Mol Cancer Ther. 2010 Aug;9(8):2243-54.
4. Albanese C, et al. Br J Pharmacol. 2013 May;169(1):156-66.
2. Degrassi A, et al. Mol Cancer Ther. 2010 Mar;9(3):673-81.
3. Albanese C, et al. Mol Cancer Ther. 2010 Aug;9(8):2243-54.
4. Albanese C, et al. Br J Pharmacol. 2013 May;169(1):156-66.
molnova catalog
related products
-
JH-VIII-49
JH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM).
-
TCS 1102
TCS 1102 is an effective, dual orexin receptor antagonist (Ki: 0.2/3 nM for OX2/1 receptors).
-
IIIM-290
IIIM-290 is a potent, orally active cyclin-dependent kinase (CDK) inhiitor with IC50 of 1.9 and 16 nM for Cdk-9/T1 and Cdk-2/A, respectively.